Literature DB >> 30354989

Elevated International Normalized Ratio Is Associated With Ruptured Aneurysms.

Anil Can1, Victor M Castro2, Dmitriy Dligach3, Sean Finan4, Sheng Yu5, Vivian Gainer2, Nancy A Shadick6, Guergana Savova4, Shawn Murphy2,7, Tianxi Cai8, Scott T Weiss9, Rose Du1,9.   

Abstract

Background and Purpose- The effects of anticoagulation therapy and elevated international normalized ratio (INR) values on the risk of aneurysmal subarachnoid hemorrhage are unknown. We aimed to investigate the association between anticoagulation therapy, elevated INR values, and rupture of intracranial aneurysms. Methods- We conducted a case-control study of 4696 patients with 6403 intracranial aneurysms, including 1198 prospective patients, diagnosed at the Massachusetts General Hospital and the Brigham and Women's Hospital between 1990 and 2016 who were on no anticoagulant therapy or on warfarin for anticoagulation. Patients were divided into ruptured and nonruptured groups. Univariable and multivariable logistic regression analyses were performed to evaluate the association of anticoagulation therapy, INR values, and presentation with a ruptured intracranial aneurysm, taking into account the interaction between anticoagulant use and INR. Inverse probability weighting using propensity scores was used to minimize differences in baseline demographics characteristics. The marginal effects of anticoagulant use on rupture risk stratified by INR values were calculated. Results- In unweighted and weighted multivariable analyses, elevated INR values were significantly associated with rupture status among patients who were not anticoagulated (unweighted odds ratio, 22.78; 95% CI, 10.85-47.81 and weighted odds ratio, 28.16; 95% CI, 12.44-63.77). In anticoagulated patients, warfarin use interacts significantly with INR when INR ≥1.2 by decreasing the effects of INR on rupture risk. Conclusions- INR elevation is associated with intracranial aneurysm rupture, but the effects may be moderated by warfarin. INR values should, therefore, be taken into consideration when counseling patients with intracranial aneurysms.

Entities:  

Keywords:  aneurysm; anticoagulants; international normalized ratio; subarachnoid hemorrhage; warfarin

Mesh:

Substances:

Year:  2018        PMID: 30354989      PMCID: PMC6205738          DOI: 10.1161/STROKEAHA.118.022412

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  25 in total

1.  The impact of aspirin and anticoagulant usage on outcomes after aneurysmal subarachnoid hemorrhage: a Nationwide Inpatient Sample analysis.

Authors:  Hormuzdiyar H Dasenbrock; Sandra C Yan; Bradley A Gross; Donovan Guttieres; William B Gormley; Kai U Frerichs; M Ali Aziz-Sultan; Rose Du
Journal:  J Neurosurg       Date:  2016-04-08       Impact factor: 5.115

2.  Dichotomal effect of the coumadin derivative warfarin on inflammatory signal transduction.

Authors:  Arnon P Kater; Maikel P Peppelenbosch; Dees P M Brandjes; Mika Lumbantobing
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

3.  The increasing incidence of anticoagulant-associated intracerebral hemorrhage.

Authors:  M L Flaherty; B Kissela; D Woo; D Kleindorfer; K Alwell; P Sekar; C J Moomaw; M Haverbusch; J P Broderick
Journal:  Neurology       Date:  2007-01-09       Impact factor: 9.910

4.  Tumor necrosis factor alpha is a key modulator of inflammation in cerebral aneurysms.

Authors:  Thottala Jayaraman; Vanessa Berenstein; Xiaguai Li; Jillian Mayer; Michael Silane; Yang Sam Shin; Yasunari Niimi; Türker Kiliç; Murat Gunel; Alejandro Berenstein
Journal:  Neurosurgery       Date:  2005-09       Impact factor: 4.654

Review 5.  Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions.

Authors:  Thorsten Steiner; Jonathan Rosand; Michael Diringer
Journal:  Stroke       Date:  2005-12-08       Impact factor: 7.914

6.  Platelet aggregation inhibitors, vitamin K antagonists and risk of subarachnoid hemorrhage.

Authors:  R Risselada; H Straatman; F van Kooten; D W J Dippel; A van der Lugt; W J Niessen; A Firouzian; R M C Herings; M C J M Sturkenboom
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

7.  Antithrombotic drugs and subarachnoid haemorrhage risk. A nationwide case-control study in Denmark.

Authors:  Anton Pottegård; Luis Alberto García Rodríguez; Frantz Rom Poulsen; Jesper Hallas; David Gaist
Journal:  Thromb Haemost       Date:  2015-07-23       Impact factor: 5.249

8.  Cerebral arterial aneurysm formation and rupture in 20,767 elderly patients: hypertension and other risk factors.

Authors:  C L Taylor; Z Yuan; W R Selman; R A Ratcheson; A A Rimm
Journal:  J Neurosurg       Date:  1995-11       Impact factor: 5.115

9.  Cigarette smoking as a cause of aneurysmal subarachnoid hemorrhage and risk for vasospasm: a report of the Cooperative Aneurysm Study.

Authors:  B K Weir; G L Kongable; N F Kassell; J R Schultz; L L Truskowski; A Sigrest
Journal:  J Neurosurg       Date:  1998-09       Impact factor: 5.115

Review 10.  Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.

Authors:  R G Hart; B S Boop; D C Anderson
Journal:  Stroke       Date:  1995-08       Impact factor: 7.914

View more
  3 in total

1.  Predictors of intraoperative intracranial aneurysm rupture in patients with subarachnoid hemorrhage: a retrospective analysis.

Authors:  Maciej J Frączek; Miłosz J Błoński; Kornelia M Kliś; Roger M Krzyżewski; Jarosław Polak; Krzysztof Stachura; Borys M Kwinta
Journal:  Acta Neurol Belg       Date:  2022-06-27       Impact factor: 2.396

2.  Associations Between Drug Treatments and the Risk of Aneurysmal Subarachnoid Hemorrhage: a Systematic Review and Meta-analysis.

Authors:  Kampei Shimizu; Tomohiro Aoki; Nima Etminan; Katharina A M Hackenberg; Shoichi Tani; Hirotoshi Imamura; Hiroharu Kataoka; Nobuyuki Sakai
Journal:  Transl Stroke Res       Date:  2022-10-15       Impact factor: 6.800

3.  Risk factors for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Valentina Opancina; Snezana Lukic; Slobodan Jankovic; Radisa Vojinovic; Milan Mijailovic
Journal:  Open Med (Wars)       Date:  2020-07-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.